文章：

COVID-19大流行对公共医疗体系中肿瘤PET/CT分期成像及患者预后的影响：大流行前两年概况与随访研究

Impact of the COVID-19 Pandemic on Staging Oncologic PET/CT Imaging and Patient Outcome in a Public Healthcare Context: Overview and Follow Up of the First Two Years of the Pandemic

原文发布日期：10 November 2023

DOI: 10.3390/cancers15225358

类型: Article

开放获取: 是

英文摘要：

To assess the impact of the COVID-19 pandemic on the diagnosis, staging and outcome of a selected population throughout the first two years of the pandemic, we evaluated oncology patients undergoing PET/CT at our institution. A retrospective population of lung cancer, melanoma, lymphoma and head and neck cancer patients staged using PET/CT during the first 6 months of the years 2019, 2020 and 2021 were included for analysis. The year in which the PET was performed was our exposure variable, and our two main outcomes were stage at the time of the PET/CT and overall survival (OS). A total of 1572 PET/CTs were performed for staging purposes during the first 6 months of 2019, 2020 and 2021. The median age was 66 (IQR 16), and 915 (58%) were males. The most prevalent staged cancer was lung cancer (643, 41%). The univariate analysis of staging at PET/CT and OS by year of PET/CT were not significantly different. The multivariate Cox regression of non-COVID-19 significantly different variables at univariate analysis and the year of PET/CT determined that lung cancer (HR 1.76 CI95 1.23–2.53,p< 0.05), stage III (HR 3.63 CI95 2.21–5.98,p< 0.05), stage IV (HR 11.06 CI95 7.04–17.36,p< 0.05) and age at diagnosis (HR 1.04 CI95 1.02–1.05,p< 0.05) had increased risks of death. We did not find significantly higher stages or reduced OS when assessing the year PET/CT was performed. Furthermore, OS was not significantly modified by the year patients were staged, even when controlled for non-COVID-19 significant variables (age, type of cancer, stage and gender).

摘要翻译： 

为评估COVID-19大流行前两年对特定人群的诊断、分期及预后的影响，我们对在本机构接受PET/CT检查的肿瘤患者进行了研究。我们纳入了2019、2020及2021年各年度前6个月内通过PET/CT进行分期的肺癌、黑色素瘤、淋巴瘤及头颈癌患者的回顾性队列进行分析。PET检查年份作为暴露变量，两个主要观察终点为PET/CT检查时的肿瘤分期和总生存期（OS）。2019-2021年各年度前6个月共完成1572例用于分期的PET/CT检查，中位年龄66岁（四分位距16岁），男性915例（58%）。肺癌是最常见的分期癌种（643例，41%）。按PET/CT年份进行的单变量分析显示，PET/CT检查时的分期与总生存期均无显著差异。多变量Cox回归分析纳入单变量分析中非COVID-19相关显著变量及PET/CT年份后发现：肺癌（HR 1.76，95%CI 1.23–2.53，p<0.05）、III期（HR 3.63，95%CI 2.21–5.98，p<0.05）、IV期（HR 11.06，95%CI 7.04–17.36，p<0.05）及诊断年龄（HR 1.04，95%CI 1.02–1.05，p<0.05）均与死亡风险增加显著相关。在评估PET/CT检查年份时，我们未发现更高分期或总生存期缩短的现象。此外，即使在控制非COVID-19相关显著变量（年龄、癌症类型、分期和性别）后，患者接受分期的年份也未对总生存期产生显著影响。

原文链接：

Impact of the COVID-19 Pandemic on Staging Oncologic PET/CT Imaging and Patient Outcome in a Public Healthcare Context: Overview and Follow Up of the First Two Years of the Pandemic